Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10428578" target="_blank" >RIV/00216208:11150/21:10428578 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/21:10428578
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-LxTAm-iyd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-LxTAm-iyd</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers13071571" target="_blank" >10.3390/cancers13071571</a>
Alternative languages
Result language
angličtina
Original language name
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Original language description
Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple myeloma during the last decade. The use of antibodies as well as antibody drug conjugates has changed the treatment landscape rapidly. The intent of this paper is to summarize the current major results of monoclonal antibody treatments in multiple myeloma. Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers
ISSN
2072-6694
e-ISSN
—
Volume of the periodical
13
Issue of the periodical within the volume
7
Country of publishing house
CH - SWITZERLAND
Number of pages
24
Pages from-to
1571
UT code for WoS article
000638353400001
EID of the result in the Scopus database
2-s2.0-85103122860